Biomarkers for immunotherapy of hepatocellular carcinoma

Nature Reviews Clinical Oncology, Published online: 19 September 2023; doi:10.1038/s41571-023-00816-4The availability of regimens containing one or more immune-checkpoint inhibitors (ICIs) has improved the outcomes in patients with advanced-stage hepatocellular carcinoma. However, clinical benefit from these regimens is difficult to predict, indicating the need for novel biomarkers. In this Review, the authors describe the available evidence on biomarkers to guide the use of ICIs in these patients and discuss promising future research directions.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research